Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

한국형 양극성 장애 약물치료 알고리듬 2018 : 우울 삽화Korean Medication Algorithm for Bipolar Disorder 2018 : Depressive Episode

Authors
서정석박원명윤보현전덕인김원이정구우영섭정종현김문두손인기심세훈송후림민경준
Issue Date
2018
Publisher
대한우울∙조울병학회
Keywords
양극성 장애; 우울 삽화; 약물치료; Bipolar disorder; Depressive episode; Pharmacotherapy; KMAP-BP 2018
Citation
우울조울병, v.16, no.2, pp 57 - 68
Pages
12
Journal Title
우울조울병
Volume
16
Number
2
Start Page
57
End Page
68
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/2678
ISSN
1738-0960
2671-4655
Abstract
2002, the fourth revision of KMAP-BP was completed in 2018 in order to reflect the recent rapid research and development into bipolar disorder and psychopharmacology. Methods : According to the methodology of previous versions, KMAP-BP 2018 was revised using a questionnaire consisting of 10 questions. Among eighty-four experts of the review committee, sixty-one completed the survey. Results : The first-line pharmacotherapeutic strategy for acute bipolar depressive episode with moderate, non-psychotic severe and psychotic severe episode was mood stabilizer (MS) combined with atypical antipsychotic (AAP) or AAP with lamotrigine. Switching or adding AAP, lamotrigine, or MS as 2nd strategies and clozapine or augmentation of buspirone, stimulant, or thyroid hormone as 3rd strategies were recommended. Compared to the previous KMAP-BP series, preference of AAP and lamotrigine has increased in the treatment of bipolar depressive episode in KMAP-BP 2018. Among the AAPs, olanzapine, quetiapine, and aripiprazole were preferred. Conclusion : Compared with the previous versions, we found that more active pharmacological strategies using AAP and lamotrigine as initial and next treatment strategies, respectively, were preferred, although few drugs were approved for bipolar depression.
2002, the fourth revision of KMAP-BP was completed in 2018 in order to reflect the recent rapid research and development into bipolar disorder and psychopharmacology. Methods : According to the methodology of previous versions, KMAP-BP 2018 was revised using a questionnaire consisting of 10 questions. Among eighty-four experts of the review committee, sixty-one completed the survey. Results : The first-line pharmacotherapeutic strategy for acute bipolar depressive episode with moderate, non-psychotic severe and psychotic severe episode was mood stabilizer (MS) combined with atypical antipsychotic (AAP) or AAP with lamotrigine. Switching or adding AAP, lamotrigine, or MS as 2nd strategies and clozapine or augmentation of buspirone, stimulant, or thyroid hormone as 3rd strategies were recommended. Compared to the previous KMAP-BP series, preference of AAP and lamotrigine has increased in the treatment of bipolar depressive episode in KMAP-BP 2018. Among the AAPs, olanzapine, quetiapine, and aripiprazole were preferred. Conclusion : Compared with the previous versions, we found that more active pharmacological strategies using AAP and lamotrigine as initial and next treatment strategies, respectively, were preferred, although few drugs were approved for bipolar depression.
Files in This Item
Go to Link
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Min, Kyung Joon photo

Min, Kyung Joon
의과대학 (의학부(임상-서울))
Read more

Altmetrics

Total Views & Downloads

BROWSE